Selventa said this week that it is partnering with drug development advisory firm Rosa and Co. to help both companies' clients make better drug discovery and development decisions, a move that David de Graaf, president and CEO of Selventa, described as an "excellent strategic fit" for his firm.
The partners plan to combine their knowledge assets, proprietary data, physiologic model libraries, and expertise in disease areas such as oncology, immunology, respiratory, inflammatory, and metabolic diseases, Selventa (formerly Genstruct) said, adding that the models and analysis will integrate genomic and transcriptomic, in vitro, animal, and clinical data.
Ron Beaver, Rosa's president and CEO, said that the collaboration will help Rosa's clients "generate mechanistic hypotheses and stratify patients" and then "evaluate them through modeling and simulation of mechanism potential, candidate drug efficacy, and ultimately patient outcomes."
As an example, "molecular mechanisms and off-target effects of our pharmaceutical partners' candidate drugs can be identified initially by Selventa's technology, and candidate compounds and effective doses can be evaluated by Rosa's PhysioPD capabilities, prior to clinical development," he said in a statement.
Founded in 2002, Rosa assists customers with decision-making during the preclinical and clinical phases of drug development with the aid of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes.
The firm currently offers two customized approaches: the pharmacokinetic/ pharmacodynamic models, which represent the mathematical and statistical relationships between dose and dose regimen, plasma drug concentration, and drug effect, and the PhysioPD models, which represent mathematical relationships between relevant physiological, pathophysiological, and pharmacological processes.
Rosa provides services around metabolic and cardiovascular diseases, oncology, gastrointestinal disease, inflammatory diseases, immune dysfunction, pain, skin conditions, respiratory ailments, as well as antibacterials and antivirals.